Targeting focal adhesion kinase signaling in tumor growth and metastasis.
about
Cyanidin-3-glucoside inhibits ethanol-induced invasion of breast cancer cells overexpressing ErbB2Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK)Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung CancerSRChing for the substrates of Src.EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinaseAn aberrant spliced transcript of focal adhesion kinase is exclusively expressed in human breast cancer.Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.The functional cancer map: a systems-level synopsis of genetic deregulation in cancerPhosphorylation of focal adhesion kinase at Tyr397 in gastric carcinomas and its clinical significance.Tailoring tyrosine kinase inhibitors to fit the lung cancer genome.PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.EphA2 Is a Potential Player of Malignant Cellular Behavior in Non-Metastatic Renal Cell Carcinoma Cells but Not in Metastatic Renal Cell Carcinoma Cells.The role of focal adhesion kinase in the TGF-β-induced myofibroblast transdifferentiation of human Tenon's fibroblasts.A novel role of sphingosine kinase-1 in the invasion and angiogenesis of VHL mutant clear cell renal cell carcinoma.PTEN, a widely known negative regulator of insulin/PI3K signaling, positively regulates neuronal insulin resistance.Focal adhesion kinase overexpression and its impact on human osteosarcoma.Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors.Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancerRole of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer.Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function.Expression of metastasis suppressor BRMS1 in breast cancer cells results in a marked delay in cellular adhesion to matrix.In Vitro and In Vivo Antimetastatic Effect of Glutathione Disulfide LiposomesNew molecular targets beyond KIT and PDGFRA in gastrointestinal stromal tumors: present and future.Targeting of the innate immunity/inflammation as complementary anti-tumor therapies.Biomarkers for predicting future metastasis of human gastrointestinal tumors.Meaningful prevention of breast cancer metastasis: candidate therapeutics, preclinical validation, and clinical trial concerns.FAK/Src family of kinases: protective or aggravating factor for ischemia reperfusion injury in nervous system?Altered miRNA expression is associated with differentiation, invasion, and metastasis of esophageal squamous cell carcinoma (ESCC) in patients from Huaian, China.When the endothelium scores an own goal: endothelial cells actively augment metastatic extravasation through endothelial-mesenchymal transition.Expression of matrix macromolecules and functional properties of EGF-responsive colon cancer cells are inhibited by panitumumab.Thyroid cancer cell lines: Critical models to study thyroid cancer biology and new therapeutic targets.Novel small molecular inhibitors disrupt the JAK/STAT3 and FAK signaling pathways and exhibit a potent antitumor activity in glioma cells.Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphologyProtein kinase G signaling disrupts Rac1-dependent focal adhesion assembly in liver specific pericytesFocal adhesion kinase inhibitors are potent anti-angiogenic agents.Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer.FAK inhibitors in Cancer, a patent review.PTK2-mediated degradation of ATG3 impedes cancer cells susceptible to DNA damage treatment.A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors.
P2860
Q23918146-8EAA8531-225E-4B37-B65B-F8DAC7541BDAQ28392664-713C39B4-D9AD-4890-B1E3-8940922C513AQ28550689-84967D03-B06A-4549-9E01-412373574016Q30457060-CEB871A3-B7B2-49B8-BDAE-43EA7096530FQ30514025-C3DE82A8-3836-4A40-BDD2-25016A9CE4FBQ33693998-CFA45AFD-6891-4731-91EE-57FC4FC478BBQ33911213-5DC1692A-1E23-4ED2-A379-BBFEF900C442Q33947216-91795EBB-06DE-4247-9B8A-EB472441332DQ34162284-7DCA8F56-3412-41C5-AAF9-1C85E9C84DC4Q34754045-E3DE7C90-CA87-44D7-ABEE-1292F51A57DEQ35691011-42928E47-E01B-4B62-9BBF-B81230529991Q35692688-F0D2F304-8810-4524-B359-A98144ADDD7AQ35707985-24811418-BFD3-4178-830B-C06422E2E95DQ35774799-3E853E1F-FB6B-4634-BD12-CE662353F976Q36284520-7A5ECEF0-8854-4FE7-A6EF-4F11D6A32CE9Q36544501-01413C83-1A3F-4D9F-B8C7-5B13ECC73A81Q36591877-475F11AE-9F4A-4840-B5F6-C036145E5A35Q36834559-9541719E-49B3-4993-B9A9-721C327B4122Q37086837-93DC2FC0-5A74-47EA-82E2-875885A22205Q37209539-85765B42-63F0-4237-BB3C-95C3F4A8C5C5Q37498587-8A20D864-3399-499E-A506-BB7CCB293C60Q37610995-2626F8AA-9F96-4498-A2DF-3A679F6705A1Q37693703-A605A2FC-B357-40FC-8D48-CB258241ACF8Q37850810-F2A03460-1038-492E-96C5-88C88F9C2FEFQ37901025-65EFB0F8-7C5F-4720-A1A6-358089C27FF5Q38078237-1C3F1B9C-7746-4234-AC9D-351F2CC7797AQ38269966-16175322-17A2-4A1A-A3D7-5953FDBB7881Q38283043-2B6F9267-19AB-4DA4-A92B-F8509C253E27Q38491448-25061C5E-DFFE-4526-BB15-DC7327FCF34AQ38780879-CA5F9596-0644-449E-869F-CE77775CD045Q39283868-07C041BE-F33B-4A93-8D73-0F4A5698474AQ39326839-53B7250E-4BC8-44BD-A0E9-4CD86B42D09CQ39354039-32770E13-9C40-4EBB-BD6E-12A11D8272F6Q39426019-DA2FF8A7-F3A8-4C1C-AD71-41FB1D8935B0Q39568078-884BB411-90F1-4F2E-B467-F6323BDE2E6EQ41133079-DAC3C7E4-FCF2-45D1-9E57-CA93276819CCQ47130626-2E575DC6-E8F2-456F-B99D-A7B81889AA51Q47797785-A468DAF8-54CC-4A5F-AE2D-C4AF47BC5C7CQ48864865-A7772623-6DEE-4CD2-BE0A-A1CAEF169953Q51297641-BC0E7611-7270-4362-8280-9A197668A7ED
P2860
Targeting focal adhesion kinase signaling in tumor growth and metastasis.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Targeting focal adhesion kinase signaling in tumor growth and metastasis.
@en
Targeting focal adhesion kinase signaling in tumor growth and metastasis.
@nl
type
label
Targeting focal adhesion kinase signaling in tumor growth and metastasis.
@en
Targeting focal adhesion kinase signaling in tumor growth and metastasis.
@nl
prefLabel
Targeting focal adhesion kinase signaling in tumor growth and metastasis.
@en
Targeting focal adhesion kinase signaling in tumor growth and metastasis.
@nl
P50
P1476
Targeting focal adhesion kinase signaling in tumor growth and metastasis.
@en
P356
10.1517/14728220903460340
P407
P577
2010-01-01T00:00:00Z